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A B S T R A C T
Purpose: There are a limited number of anticonvulsant medications that can be administered with an
oral loading dose in order to rapidly achieve an effective serum level, and most of these have associated
adverse effects. Zonisamide is approved for the treatment of partial onset epilepsy, and is used in practice
for both generalized and partial onset epilepsy. It is generally well-tolerated, has a long half-life, and can
be administered once daily. Unfortunately, the recommended titration schedule for initiating therapy
takes several weeks to reach target dose and therapeutic serum levels.
Methods: We initiated zonisamide therapy using a large initial dose of zonisamide in 32 patients in our
epilepsy monitoring unit over the past four years.
Results: Adverse effects were rare and involved nausea/vomiting (9.4%) or drowsiness (6.3%). In patients
where serum levels were available for review, therapeutic or near-therapeutic levels were achieved after
an oral load of 600–900 mg given as divided doses over a 6–12 h period.
Conclusion: This report is the ﬁrst to suggest a method of rapidly initiating zonisamide therapy,
achieving therapeutic serum levels in a shorter time frame, with an adverse effect proﬁle similar to the
recommended titration schedule.
 2015 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
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Zonisamide is an anticonvulsant drug well tolerated as
monotherapy in patients with partial onset epilepsy, and also
effective for the treatment of generalized epilepsy. The mechanism
by which zonisamide acts is thought to be the blocking of voltage-
sensitive sodium and T-type calcium channels, resulting in
stabilization of neuronal membranes and suppression of neuronal
hypersynchronization. It is remarkable for its long half-life
(63–69 h), allowing for once-a-day dosing. Zonisamide is rapidly
and completely absorbed, with peak absorption occurring at 2–6 h,
and metabolism occurring primarily through cytochrome P450
isozyme 3A4 (CYP3A4), followed by renal excretion [1,2]. It takes
10–12 days to reach steady state serum levels. Typically dosed at
100–600 mg daily with a recommended therapeutic range of
10–40 mcg/mL [3], it is routinely initiated as 100 mg daily with
uptitration 100 mg every week. Depending on the effective dose,
with this titration schedule, it may take 4–6 weeks to reach a
steady state therapeutic serum level. We administered a large
initial dose of zonisamide, which we termed a ‘‘loading dose’’, to 32* Corresponding author. Present address: NYU Langone Epilepsy Center, 223 East
34th Street, New York, NY 10016, USA. Tel.: +1 3193312275.
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achieving a therapeutic serum level more quickly than the
recommended titration schedule allows, to facilitate discharge
and decrease hospital length of stay. We found that this was both a
safe and well-tolerated method of initiating zonisamide therapy.
2. Methods
Our retrospective study included 32 adult (age >18) inpatients
of the epilepsy monitoring unit of Columbia University Medical
Center from 2011 to 2015, who were initiated on zonisamide
therapy during their hospitalization using a ‘‘loading dose’’ which
was deﬁned as three times the target maintenance dose, given in
two divided doses, 6 h apart. In most cases, the reason for using a
large initial dose was the desire to achieve a therapeutic serum
zonisamide level before discharging the patient. In one case,
treatment of refractory focal seizures was the reason for rapid
initiation of zonisamide. The large initial dose was given on the
ﬁrst day of therapy, and the initial maintenance dose (usually
200 mg or 300 mg daily) was begun the next day. Serum levels
were drawn after administration of the complete dose. Information
from follow-up visits, including zonisamide side effects and serum
levels were also noted when available. Adverse effects to
zonisamide during the hospital stay or immediately upon
discharge were gathered from the physician notes, nursing notes,served.
Table 1
Patient characteristics and zonisamide dosing information.
n 32
Age 43 (20–69) yearsa
Gender 50% women
Height 170 (150–185) cm
Weight 80 (47–110) kg
Body mass index (BMI) 28 (17–41) kg/m2
Epilepsy type 28 focal onset 4
primary generalized
Hepatic impairment prior to load 2
Renal impairment prior to load 0
Taking other anticonvulsants 18
Total initial dose 600 (400–900) mg
Time period administered 6 (5–15) h
Serum level after completed dose 10 (6–15) mcg/mL
Time until hospital discharge after dose 2 (1–15) days
a All values are listed as median (range) unless otherwise speciﬁed.
Fig. 1. Nausea was the most common side effect reported after administration of a
‘‘loading’’ dose of zonisamide (blue bars, n = 32). At follow-up, cognitive side effects
included mood instability, aggressiveness, and depression (red bars, n = 25). (For
interpretation of the references to color in this ﬁgure legend, the reader is referred
to the web version of this article.)
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Institutional Review Body of Columbia University Medical Center
and informed consent was waived for this study.
3. Results
32 adults were included in this analysis, outlined in Table 1.
Zonisamide was used as monotherapy in 14 patients, dual therapy
in 12, and polytherapy in six. Other anticonvulsant drugs included
levetiracetam (9), lacosamide (4), phenytoin (3), carbamazepine
(2), oxcarbazepine (2), pregabalin (2), valproate (2), and gaba-
pentin (1). The total initial dose was 400–900 mg, divided in 2–3
doses over 4.5–15 h. Most of the patients (26) received 600 mg
(two divided doses) as the initial dose. Two patients received a
total initial dose of 900 mg (3 divided doses) and four patients
received 400 mg (as a single or divided dose). Most divided doses
were given 5–7 h apart, in order to improve tolerability.
Five of the 32 patients reported side effects (Fig. 1). Two
patients complained of tiredness (6.3%), one of whom had also
been given benzodiazepines. Three patients (9.4%) had nausea or
vomited: 1 patient had intractable nausea and vomiting for 5 days
until the zonisamide was discontinued, a second patient vomited
once within 12 h of the ﬁrst dose and had no further side effects,
and a third patient complained of only nausea, which resolved
within several hours after the ﬁrst dose. The average post-load
serum level in patients with nausea/vomiting was 11 mcg/mL. Side
effects were not more common in patients who were on multiple
anticonvulsant medications. 25 patients were seen in follow-up.
The median length of time to follow-up was 11 months. Of these,
12 patients (48%) complained of side effects, and 7 (28%)
discontinued zonisamide because of side effects (Fig. 1). TheTable 2
Zonisamide levels in 12 patients after a large initial dose.
Patient Gender Age Weight
(kg)
Diagnosis Total
zonisam
dose (m
1 F 51 81.7 Temporal lobe epilepsy 900 
2 F 22 81.7 Frontal lobe epilepsy 600 
3 F 49 79.0 Localization related epilepsy 600 
4 F 59 73.8 Left temporal low grade glioma 600 
5 F 27 83.5 Juvenile myoclonic epilepsy 600 
6 F 20 46.7 Localization related epilepsy 600 
7 M 23 88.4 Temporal lobe epilepsy 900 
8 F 47 74.0 Left temporal lobe epilepsy 600 
9 M 42 83.9 Meningioma 600 
10 M 28 97.0 Localization related epilepsy 600 
11 M 23 58.6 Periventricular heterotopias 600 
12 M 58 73.0 Multifocal epilepsy 600 median length of time to discontinue zonisamide was 7 months
(range, 3 days–23 months).
Serum levels were drawn in 12 of the 32 patients (Table 2). The
median zonisamide level was therapeutic at 10 mcg/mL, including
four patients who were also on enzyme-inducing anticonvulsants.
The earliest therapeutic level was seen 2 h after the large initial
dose and was 15 mcg/mL. There was no signiﬁcant trend between
total initial dose and serum level, but 100% of patients who
received a total of 900 mg had a therapeutic level, whereas only
40% of patients who received a total 600 mg had a therapeutic
level. The median zonisamide level at follow-up was 14.5 mcg/mL.
4. Discussion
An oral ‘‘loading dose’’ of zonisamide in these patients was
generally well-tolerated. Nausea/vomiting and tiredness were the
only reported adverse effects and occurred in 15% of our patients. It
is notable that after a large initial dose of zonisamide, gastrointes-
tinal (GI) adverse effects were more common than central nervous
system (CNS) side effects, although CNS side effects were more
common at follow-up, as they were in clinical trials. It is possible
that GI side effects could have been mitigated by administration ofide
g)
Given
as. . .
Time
between
doses (h)
Serum
level after
total dose
(mcg/mL)
Time to
level after
total dose (h)
Concomitant
anti-convulsants
300  3 6 15 2
300  2 6.5 9 4.5 OXC/LAC
300  2 10 10 6
300  2 12 8 5 VPA
300  2 6 9 12
300  2 6 12 6 PHT
300  3 6 11 14 LEV
300  2 6 10 8
300  2 5 6 3
300  2 6 6 7
300  2 6 10 12 OXC/LEV
300  2 6 7 12
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trials [4,9] that adverse events are higher in most categories when
titration of zonisamide is more rapid; however, we did not note a
signiﬁcantly higher rate of adverse events despite a cumulative
dose of up to 900 mg in <24 h. Other published reports of high-
dose zonisamide ingestion include three cases of overdose, two of
which resulted in hypotension, respiratory depression or cardiac
arrest and coma in combination with other medications [5,6]. The
third case was an ingestion of 8.7 g of zonisamide, with a plasma
level of 110 mg/L at 5.5 h after ingestion, in which the patient
suffered from only nausea, chest pain, blurred vision, dizziness and
headache, without any metabolic derangements or cardiopulmo-
nary side effects [7]. This suggests that serious adverse events are
unlikely to occur from a much lower dose. Side effects may be
underestimated in this report, as all were self-reported and not
elicited by questionnaire, and depended on the reliable reporting
of any noted side effects in the chart. Also there is probably a
selection bias, as patients chosen for a large initial dose were likely
to be young, otherwise healthy, without renal or hepatic
impairment, and less likely to be on anticonvulsant drug
polytherapy. The adverse effect rate of long-term follow-up
(48% adverse effects, with 28% discontinuing zonisamide) com-
pares with other studies showing rates of 51–61% treatment
related adverse effects and 19% resulting in drug discontinuation
[8,9]. The most common adverse effects reported in previous
zonisamide trials include ataxia, dizziness, somnolence, tiredness,
nausea, headache, agitation, and anorexia [8], which agrees with
our long-term follow-up results. Phenytoin, carbamazepine, and
valproate are other anticonvulsant medications that are orally
loaded. Oral phenytoin at 20 mg/kg oral loading dose takes 4–8 h
to reach therapeutic levels, with up to 50% of patients experiencing
dizziness, nausea/vomiting, drowsiness, and nystagmus [10,11].
Oral loading of carbamazepine result in therapeutic levels 4–18 h
after administration with adverse effects in 30–60% of patients of
dizziness, nausea, drowsiness, and nystagmus [12]. Oral loading of
valproate up to 20 mg/kg resulted in GI upset, dizziness or sedation
in up to 50% of patients [13]. In this small series, the adverse effect
rate of 16% suggests that zonisamide may actually be better
tolerated.
No conclusions regarding optimal loading dose or pharmacoki-
netics of zonisamide loading can be drawn from this limited study,
because timed blood levels were not collected for all the patients.
Serum levels were drawn in 12 patients, and indicate that a
detectable serum zonisamide level is obtained after an initial dose
of 600–900 mg. It is noteworthy that the patients who received
900 mg were more likely to have a therapeutic level than those
who had received 600 mg zonisamide. Based on this experience wewould recommend a dose of 900 mg. We were concerned primarily
about safety and tolerability in this small group of patients,
therefore we did not formally calculate a loading dose based on
volume of distribution (0.9–1.4 L) and target concentration
(10–15 mcg/mL), but had we done so, the result would have been
600–1500 mg.
5. Conclusion
This is the ﬁrst report of its kind to suggest a safe and well-
tolerated method for the rapid initiation of zonisamide therapy
using an oral ‘‘loading dose’’. This may be useful in patients who
need rapid control of seizures or are anticipating imminent
hospital discharge on zonisamide monotherapy.
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